Core Viewpoint - The company has approved a share repurchase plan to enhance shareholder value and implement employee stock ownership plans, with a total repurchase fund ranging from RMB 30 million to RMB 60 million [2] Group 1: Share Repurchase Plan - The company will repurchase shares using its own funds through centralized bidding, with a maximum repurchase price set at RMB 160.26 per share [2] - The implementation period for the repurchase aimed at employee stock ownership plans is within 12 months from the board's approval, while the repurchase for maintaining company value must be completed within 3 months [2] - The maximum repurchase price was adjusted to RMB 159.27 per share effective from June 12, 2025, following the annual equity distribution [3] Group 2: Progress of Share Repurchase - As of January 31, 2026, the company has repurchased a total of 454,300 shares, accounting for approximately 0.66% of the total share capital, with a total transaction amount of RMB 34,382,590.35 [3] - The highest transaction price during the repurchase was RMB 79.99 per share, while the lowest was RMB 74.03 per share [3] Group 3: Compliance and Regulations - The share repurchase complies with relevant laws, regulations, and the company's repurchase plan [4] - The company has adhered to the stipulations regarding the timing and conditions under which shares can be repurchased, ensuring no repurchase occurs during significant events that could affect stock prices [5]

Group 1 - The company announced the resignation of Vice General Manager Chen Wenjun due to reaching the legal retirement age, effective from the date the resignation report was received by the board [2] - Chen Wenjun held 3.12 million shares of the company at the time of his resignation and has completed the necessary work handover, ensuring that his departure will not impact the company's operations [2] - The company confirms that Chen Wenjun's resignation will be managed according to relevant laws and regulations regarding the shares held by directors and senior management [2]

Core Viewpoint - The company has approved adjustments to the investment amounts of its fundraising projects and plans to provide interest-free loans to its wholly-owned subsidiaries to ensure the smooth implementation of these projects [2][4][24]. Group 1: Board Meeting Details - The first session of the board of directors' sixteenth meeting was held on February 2, 2026, with all six directors present, complying with relevant laws and regulations [1][3]. - The meeting reviewed and approved the proposal to adjust the investment amounts for fundraising projects, which was previously approved by the audit committee [2][4]. Group 2: Fundraising and Financial Details - The company raised a total of approximately RMB 1.24 billion through its initial public offering, with a net amount of approximately RMB 1.13 billion after deducting related expenses [8][18]. - The company plans to adjust the investment amounts for its fundraising projects due to the actual net amount being lower than the originally planned investment [10][19]. Group 3: Loan to Wholly-Owned Subsidiaries - The company will provide RMB 19.28 million and RMB 25.85 million as interest-free loans to its wholly-owned subsidiaries, Ningbo Zhixin and Anhui Zhixin, respectively, for the implementation of fundraising projects [17][20]. - The loans are intended solely for the specified projects and will not be used for other purposes [20][24]. Group 4: Compliance and Oversight - The audit committee and the sponsor have both expressed their agreement with the adjustments and the loan provisions, confirming that these actions comply with relevant regulations and do not harm shareholder interests [13][27]. - The company has established special accounts for the management of the raised funds to ensure their safe use [25].

Group 1 - The core announcement is that Jiangsu Hengrui Medicine Co., Ltd. has received a confirmation letter from the FDA regarding the acceptance of its Biologics License Application (BLA) for injection of Carrelizumab combined with Apatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma [1] - The target review date set by the FDA for the BLA is July 23, 2026, under the Prescription Drug User Fee Act (PDUFA) [1] - The drug Carrelizumab is a humanized anti-PD-1 monoclonal antibody that restores the body's anti-tumor immunity by blocking the PD-1/PD-L1 pathway [5] Group 2 - The clinical trial for Carrelizumab combined with Apatinib was approved in December 2018 and achieved orphan drug designation from the FDA in April 2021 [2] - The Phase III clinical trial (SHR-1210-III-310) demonstrated significant survival benefits, with a median progression-free survival (PFS) of 5.6 months and a median overall survival (OS) of 22.1 months, which was later updated to 23.8 months [3] - The study involved 543 participants and compared the efficacy and safety of Carrelizumab combined with Apatinib against Sorafenib, marking it as the first successful Phase III trial of immunotherapy combined with a small molecule tyrosine kinase inhibitor for advanced hepatocellular carcinoma [3] Group 3 - The total research and development investment for Carrelizumab has reached approximately 319.74 million yuan (unaudited) [5] - The global sales of anti-PD-1 antibodies are projected to be around 41.546 billion USD in 2024 [5] - The company plans to continue advancing the project and will fulfill its information disclosure obligations regarding subsequent developments [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 三、其他事项 浙江嘉化能源化工股份有限公司(以下简称"公司")分别于2025年4月9日、2025年4月30日召开第十届董 事会第十一次会议、2024年年度股东大会，审议通过了《关于以集中竞价交易方式回购股份方案的议 案》，同意公司以不低于人民币40,000万元、不超过人民币60,000万元的自有资金及自筹资金通过集中 竞价交易方式回购股份，回购价格为不超过12.01元/股，回购期限为自股东大会审议通过回购股份方案 之日起不超过12个月(以下简称"2025年回购计划")。有关本次回购股份事项的具体情况详见公司于2025 年4月10日及2025年5月1日在上海证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方 式回购股份方案的公告》、《关于以集中竞价交易方式回购股份的回购报告书》。经公司实施2024年年 度利润分配方案及2025年半年度利润分配方案后，公司以集中竞价方式回购股份的价格上限由不超过人 民币12.01元/股逐步调整为不超过人民币11.63元/股。详见公司在上海证券交易所网站 （www.sse.com.cn）披露的《关于调整回购股 ...

江苏恒瑞医药股份有限公司 关于董事会延期换届的提示性公告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-020 2026年2月2日 江苏恒瑞医药股份有限公司(以下简称"公司")第九届董事会已于 2026 年2月1日任期届满。鉴于公司新 一届董事会换届相关工作正在筹备中，为保证公司董事会相关工作的连续性和稳定性，公司董事会的换 届选举工作将适当延期，董事会各专门委员会、高级管理人员的任期亦相应顺延。 在新一届董事会换届选举工作完成前，公司第九届董事会全体董事、董事会各专门委员会成员及高级管 理人员将继续按照相关法律法规和《公司章程》等规定，履行董事及高级管理人员的职责和义务。 公司董事会换届延期不会影响公司的正常运营，公司正在积极推进，尽快完成董事会的换届选举工作， 并及时履行信息披露义务。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 特此公告。 江苏恒瑞医药股份有限公司董事会 ...

Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where all resolutions were approved without any objections from shareholders [1][4]. Group 1: Meeting Details - The meeting took place on February 2, 2026, at 14:30, combining both on-site and online voting methods [2][3]. - A total of 428 shareholders attended the meeting, representing 564,612,468 shares, which is 42.1124% of the total voting shares [4][20]. - The meeting was convened by the company's board of directors and presided over by Chairman Fang Zhengji [7][24]. Group 2: Voting Results - The first proposal regarding the expected daily operational related party transactions for 2026 received 94.4415% approval, with 8,487,678 shares in favor [9][27]. - The second proposal to amend the fundraising management system was approved with 98.8351% support, totaling 558,035,242 shares in favor [10][29]. - Notably, the controlling shareholder, Dongfang Electronics Group Co., Ltd., and its concerted party abstained from voting on the first proposal [9][30]. Group 3: Legal Opinions - The meeting's procedures, including the convening and voting processes, were confirmed to comply with relevant laws and the company's articles of association by the legal counsel from Beijing Huada Law Firm [12][19]. - The legal opinion stated that the qualifications of attendees and the voting procedures were valid and met all regulatory requirements [25][30].

登录新浪财经APP 搜索【信披】查看更多考评等级 （1）自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发生之日或者在决策过程中， 至依法披露之日内； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 潍柴动力股份有限公司（下称"公司"）于2025年4月29日召开2025年第四次临时董事会会议，于2025年5 月20日召开2025年第二次临时股东大会、2025年第二次A股股东会议和2025年第二次H股股东会议，审 议通过了《关于回购公司部分A股股份方案的议案》，同意公司使用自有资金和自筹资金以集中竞价交 易方式回购公司部分A股股份，回购股份用于注销并减少公司注册资本，回购价格为不超过人民币23.57 元/股，预计用于回购的资金总额不低于人民币5亿元，不超过人民币10亿元，回购期限为自公司股东大 会审议通过回购股份方案之日起12个月内。具体内容详见公司分别于2025年4月30日、2025年5月21日、 2025年6月4日在巨潮资讯网（http://www.cninfo.com.cn）上披露的《潍柴动力股份有限公司关于回购公 司部分A股股份的方案》《潍柴动 ...

Core Viewpoint - The company has initiated its tenth employee stock ownership plan, which was approved by the board and shareholders, and has opened a dedicated securities account for this plan [1][2]. Group 1: Employee Stock Ownership Plan - The company held its sixth board meeting on November 14, 2025, and a temporary shareholders' meeting on December 2, 2025, where the employee stock ownership plan was approved [1]. - The tenth employee stock ownership plan was officially implemented, with a dedicated securities account opened on December 8, 2025, at the Shenzhen branch of China Securities Depository and Clearing Corporation [1]. - As of February 2, 2026, the company has not yet purchased any stocks under the tenth employee stock ownership plan [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●已履行及拟履行的审议程序：杭州福莱蒽特股份有限公司（以下简称"公司"）于2025年4月25日召开第 二届董事会第十次会议、第二届监事会第九次会议，以及2025年5月21日召开2024年年度股东大会审议 通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在确保募投项目资金需求和资金 安全的前提下，使用最高额不超过人民币86,000万元的暂时闲置募集资金进行现金管理，用于购买安全 性高、流动性好的理财产品、结构性存款及其他低风险投资产品。上述额度自2024年年度股东大会审议 通过之日起12个月内有效，单个理财产品或结构性存款的投资期限不超过12个月，相关投资在上述额度 及决议有效期内可以循环滚动使用。保荐机构对上述事项发表了明确的同意意见。 ●特别风险提示：公司购买的是安全性高、流动性好、满足保本条件的单位大额存单，但仍存在银行破 产倒闭带来的清算风险、政策风险、流动性风险、不可抗力风险等风险。 一、投资 ...